| Name | Title | Contact Details |
|---|
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea.
Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.
Gradientech is developing the microfluidic platform of tomorrow, today. Our revolutionising in vitro diagnostic system, QuickMIC®, is designed to strengthen labs by providing reliable results, at outstanding speed. Visit to experience how.
Stelexis` mission is to become the leading cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).